US transformation has been successful, says Novo Nordisk's country head

Pharmaceutical firm Novo Nordisk is very close to attaining the goals set for its US operation. According to Doug Langa, Novo’s head in the country, diabetes drug Ozempic is sprinting ahead whereas pill treatment Rybelsus is lagging behind.

Doug Langa, executive vice president, head of North America operations and president of Novo Nordisk | Photo: Novo Nordisk / PR

Pharmaceutical firm Novo Nordisk has made it in the US, at least according to the company’s head of operations in the country, Doug Langa.

”It has been successful,” says Doug Langa, whose full title at Novo Nordisk is Executive Vice President, Head of North America Operations and President.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs